Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 1/2 2Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 444CNS 53Thoracic 51Sarcoma 29Breast 17Tumor-Agnostic 10Genitourinary 8Gynecologic 7Endocrine 6Other solid neoplasm 5Lymphoid 4Head & Neck 4Other hematologic neoplasm 3NET 2Dermatologic 1Classical hematology 1

Conditions

Neoplasms, Unknown Primary 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19HhAntag691 19Mycophenolic Acid 18Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Irinotecan × Dermatologic × Clear all
NCT00004922 2013-06-19

Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
DermatologicEndocrine

Neoplasms, Unknown Primary, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡